Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H21N5O4.C6H5NO2 |
Molecular Weight | 434.4463 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CN=CC=C1.CN(CCO)CC(O)CN2C=NC3=C2C(=O)N(C)C(=O)N3C
InChI
InChIKey=GEPMAHVDJHFBJI-UHFFFAOYSA-N
InChI=1S/C13H21N5O4.C6H5NO2/c1-15(4-5-19)6-9(20)7-18-8-14-11-10(18)12(21)17(3)13(22)16(11)2;8-6(9)5-2-1-3-7-4-5/h8-9,19-20H,4-7H2,1-3H3;1-4H,(H,8,9)
Xanthinol (xanthinol nicotinate) is a xanthine derivative, peripheral vasodilator agent. It exerts it`s pharmacological action by acting as a vasodilator and improves blood flow to brain, arteries, and to the periphery. It increases brain glucose metabolism and thus improves brain ATP levels. It stimulates memory and concentration elevates brain energy levels. Indications for Xanthinol Nicotinate:
1. Peripheral vascular sclerosis
2. Cerebral circulatory disorders
3. Arteriosclerosis
4. Endarteritis obliterans
5. Short term memory disorders
6. Mental flagging
7. Anti ageing memory support
8. Diabetic angiopathy
9. Diabetic gangrene
10. Hyperlipidaemia
11. Intermittent claudication
Side Effects of Xanthinol Nicotinate:
1. Flushing
2. Feeling of warmth
3. Nausea
4. Heart burn
5. Vomiting
6. Itching of skin
For 30 years, Xanthinol nicotinate has been on the market for the treatment of impaired brain function, i.e., organic brain syndromes of various etiologies. Controlled double-blind phase-III clinical trials have shown that xantinol nicotinate is also an effective drug in the treatment of dementia. Xanthinol nicotinate is also helpful in the management of leg ulcers associated with haemoglobinopathies.
Xanthinol was approved as a drug in 1998 in Canada and nowadays its status is cancelled post marketing. The positively charged xanthinol ion is thought to help the transportation of the nicotinic acid into the cell since the later cannot freely diffuse through the cell membrane. The mechanism of action is thought to be related to present influence in the cell metabolism through the nucleotides NAD and NADP. Also, the nicotinic acid is a coenzyme for a lot of proteins involved in tissue respiration (Embden-Meyerhof and citrate cycle). The effect of xanthinol nicotinate causes an increase in glucose metabolism and energy gain.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Complamin Approved UseXanthinol Nicotinate (Complamin) is a vasodilator used for the treatment of Peripheral vascular disease, Cerebrovascular disorders and other conditions. |
|||
Primary | Complamin Approved UseXanthinol Nicotinate (Complamin) is a vasodilator used for the treatment of Peripheral vascular disease, Cerebrovascular disorders and other conditions. Launch Date1992 |
PubMed
Title | Date | PubMed |
---|---|---|
Psoriasis and side-effects of mesotherapy. | 2001 Sep |
|
[Pathogenetic basis for using prodectin and teonicol, redergin and aescuzan in complex treatment of chronic gastritis]. | 2002 |
|
[Sudden hearing loss--our experience in treatment with vasoactive therapy]. | 2008 Mar-Apr |
|
Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of xanthinol in human plasma and its application in a bioequivalence study of xanthinol nicotinate tablets. | 2008 Sep 15 |
|
Novel inhibitors of HIV discovered among existing classes of pharmaceutical compounds indicated for unrelated clinical indications. | 2009 |
|
Use of Xanthinol Nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors. | 2010 Jan 15 |
|
[Peyronie's disease: comparative results of conservative treatment]. | 2010 Nov-Dec |
Sample Use Guides
Typical Dosage for Xanthinol Nicotinate
Oral: 300mg 8th hourly. Increases the dosage up to 600mg 8th hourly if required.
Maximum dose: 1800mg/day.
I.V. or I.M.: 300mg.
Maximum dose: 900mg.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26718554
HUASMCs were treated with different concentrations of Xanthinol (xanthinol nicotinate) (0, 2.76, 27.6 or 276 uM), and a 3-(4,5-dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was used to detect the inhibition of HUASMC proliferation.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
||
|
WHO-VATC |
QC04AD02
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
||
|
DSLD |
3116 (Number of products:10)
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
||
|
WHO-ATC |
C04AD02
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
113217
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY | |||
|
9912
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY | |||
|
DTXSID0023743
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY | |||
|
C152928
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY | |||
|
8G60H12X2D
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY | |||
|
1492
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY | |||
|
207-115-7
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY | |||
|
DBSALT001141
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY | |||
|
11358
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY | RxNorm | ||
|
m11528
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB00097MIG
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY | |||
|
XANTINOL NICOTINATE
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY | |||
|
100000092586
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY | |||
|
437-74-1
Created by
admin on Fri Dec 15 19:00:11 GMT 2023 , Edited by admin on Fri Dec 15 19:00:11 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
ACTIVE MOIETY
SUBSTANCE RECORD